Susan Leander, RN, BSN, serves as the Director of Patient Access for the Northeast region within Amgen's Rare Disease Business Unit, specifically focusing on KRYSTEXXA, a critical treatment for chronic gout. In this pivotal role, Susan leads a dedicated team of eight patient access and...
Susan Leander, RN, BSN, serves as the Director of Patient Access for the Northeast region within Amgen's Rare Disease Business Unit, specifically focusing on KRYSTEXXA, a critical treatment for chronic gout. In this pivotal role, Susan leads a dedicated team of eight patient access and reimbursement specialists, ensuring that patients have seamless access to this innovative therapy. With over 15 years of experience in the pharmaceutical and biotech industries, Susan has cultivated a deep understanding of the complexities surrounding patient access, reimbursement strategies, and the regulatory landscape.
Her expertise spans various therapeutic areas, including rare diseases, where she has successfully navigated the intricacies of Medicare and private insurance reimbursement processes. Susan's strong analytical skills enable her to assess market trends and patient needs, allowing her team to develop tailored strategies that enhance patient education and support. Furthermore, her background in sales equips her with exceptional communication skills, fostering strong relationships with healthcare providers, payers, and patients alike.
Key projects under Susan's leadership include the implementation of innovative patient support programs that not only streamline access to KRYSTEXXA but also empower patients through education about their treatment options. Her commitment to customer service ensures that patients receive the guidance they need throughout their treatment journey, ultimately improving health outcomes. As a thought leader in patient access, Susan continues to advocate for policies that enhance accessibility to life-changing therapies, making a significant impact in the realm of rare diseases.
